Regeneron Pharmaceuticals Stock Rating Lowered by Zacks (REGN)
Regeneron Pharmaceuticals (NASDAQ:REGN) was downgraded by Zacks from an “outperform” rating to an “underperform” rating in a report released on Tuesday. They currently have a $316.00 price target on the stock. Zacks‘s price target points to a potential downside of 9.17% from the company’s current price.
Zacks’ analyst wrote, “We are downgrading Regeneron to Underperform following its earnings miss by a wide margin in the second quarter of 2014. The company’s reported earnings of $1.89 per share were well short of the Zacks Consensus Estimate of $2.33 due to higher costs. Regeneron’s earnings estimates for 2014 and 2015 have gone down following the disappointing bottom-line performance. Though impressed by the rebound in U.S. sales of Eylea in the second quarter from a disappointing first quarter, we believe that sales of the eye drug will have to improve significantly in the remaining quarters in order to meet the 2014 guidance of $1.7 billion to $1.8 billion. We believe that there is significant scope for stock price depreciation from current levels and advise investors to get rid of it.”
In other Regeneron Pharmaceuticals news, VP Michael S. Aberman sold 3,611 shares of Regeneron Pharmaceuticals stock on the open market in a transaction that occurred on Tuesday, August 19th. The stock was sold at an average price of $350.00, for a total value of $1,263,850.00. The sale was disclosed in a filing with the SEC, which is available at this link.
REGN has been the subject of a number of other recent research reports. Analysts at RBC Capital raised their price target on shares of Regeneron Pharmaceuticals from $349.00 to $373.00 in a research note on Wednesday, August 6th. They now have an “outperform” rating on the stock. Separately, analysts at Roth Capital reiterated a “buy” rating on shares of Regeneron Pharmaceuticals in a research note on Tuesday, August 5th. Finally, analysts at Deutsche Bank raised their price target on shares of Regeneron Pharmaceuticals from $410.00 to $425.00 in a research note on Tuesday, August 5th. They now have a “buy” rating on the stock. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and fifteen have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $344.28.
Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) traded up 1.56% during mid-day trading on Tuesday, hitting $353.33. 386,465 shares of the company’s stock traded hands. Regeneron Pharmaceuticals has a 1-year low of $235.02 and a 1-year high of $353.05. The stock has a 50-day moving average of $323.9 and a 200-day moving average of $311.5. The company has a market cap of $35.471 billion and a price-to-earnings ratio of 99.01.
Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $2.47 EPS for the quarter, beating the Thomson Reuters consensus estimate of $2.30 by $0.17. The company had revenue of $666.00 million for the quarter, compared to the consensus estimate of $647.99 million. During the same quarter in the prior year, the company posted $1.73 earnings per share. The company’s quarterly revenue was up 45.4% on a year-over-year basis. On average, analysts predict that Regeneron Pharmaceuticals will post $10.15 earnings per share for the current fiscal year.
Regeneron Pharmaceuticals, Inc (NASDAQ:REGN) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.
To view Zacks’ full report, visit Zacks’ official website.
Receive News & Ratings for Regeneron Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.